{"id":63107,"date":"2026-05-14T19:03:05","date_gmt":"2026-05-14T17:03:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/"},"modified":"2026-05-14T19:03:05","modified_gmt":"2026-05-14T17:03:05","slug":"covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/","title":{"rendered":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET.<\/p>\n

<\/a>
<\/a><\/p>\n

\nTo view, listen to, and participate in the live webcast, please follow the link below:<\/p>\n

\nhttps:\/\/events.q4inc.com\/attendee\/485973962<\/a><\/p>\n

\nTo listen and participate via the conference call, please dial:<\/p>\n

\nUSA Toll-Free: 1-800-715-9871
\n
Canada Toll-Free: 1-800-715-9871
\n
Local (Toronto): 647-932-3411
\n
Conference ID: 4934172<\/p>\n

\nParticipants will be able to ask questions during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast.<\/p>\n

\nA recording of the call will be available on www.covalon.com<\/a> under News & Events on the Investors tab.<\/p>\n

\nCopies of Covalon\u2019s financial statements and MD&A can be obtained on SEDAR PLUS at www.sedarplus.ca<\/a> and under SEDAR Filings on the Investors tab of Covalon\u2019s website.<\/p>\n

\nThose interested in learning about Covalon\u2019s solutions may visit www.covalon.com<\/a> or follow Covalon on LinkedIn<\/a>, Facebook<\/a>, Instagram<\/a>, or X<\/a>.<\/p>\n

\nAbout Covalon
\n
<\/b>Covalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com<\/a>.<\/p>\n

\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/p>\n

\nThis news release may contain forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as \u201cseek\u201d, \u201canticipate\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cintend\u201d, or variations of such words and phrases or state that certain actions, events, or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cwill\u201d or \u201cwill be taken\u201d, \u201coccur\u201d, or \u201cbe achieved\u201d. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management\u2019s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the \u201cRisks and Uncertainties\u201d section of our management\u2019s discussion and analysis of financial condition and results of operations for the year ended September 30, 2025, which is available on the Company\u2019s profile at <\/i>www.sedarplus.ca<\/i><\/a>, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nTo learn more about Covalon, please contact:<\/p>\n

Brent Ashton, Chief Executive Officer, Covalon Technologies Ltd.
\n
Email: investors@covalon.com<\/a>
Phone: 1.877.711.6055
\n
Website: https:\/\/covalon.com\/<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-63107","6":"format-standard","7":"category-industry"},"yoast_head":"\nCovalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T17:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results\",\"datePublished\":\"2026-05-14T17:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/\"},\"wordCount\":601,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260514447865\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/\",\"name\":\"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260514447865\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"datePublished\":\"2026-05-14T17:03:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260514447865\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260514447865\\\/en\\\/1767588\\\/22\\\/Covalon_News_Release_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/","og_locale":"en_US","og_type":"article","og_title":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-14T17:03:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results","datePublished":"2026-05-14T17:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/"},"wordCount":601,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/","url":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/","name":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","datePublished":"2026-05-14T17:03:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260514447865\/en\/1767588\/22\/Covalon_News_Release_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/covalon-announces-conference-call-to-discuss-second-quarter-fiscal-2026-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63107"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63107\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}